You are here: Industry Insights > ABL

News List

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody prnasia
August 05, 2021
ABL Bio, Inc. announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea's Ministry of Food and Drug Safety (MFDS).
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody prnasia
July 12, 2021
ABL Bio, Inc. announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC).
Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie contractpharma
March 08, 2021
Pharmaron Beijing has entered into a definitive agreement to acquire Allergan Biologics Limited (ABL) in Liverpool, UK, for $118.7 million from AbbVie.
Just - Evotec Biologics, ABL Enter Clinical Supply Pact contractpharma
June 10, 2020
Just - Evotec Biologics to design a manufacturing process for the production of Phase I cGMP clinical supply of a broadly neutralizing antibody against HIV.
ABL Supports Fill/Finish of COVID-19 Vaccine Candidate contractpharma
April 20, 2020
Utilizes its aseptic fill/finish facility to support confidential clients' COVID-19 vaccine development.
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Novel Immune Check Point Bispecifics for $220 Million en-cphi.cn
March 01, 2019
WuXi Biologics and ABL Bio Corporation announced the expansion of their strategic partnership for novel bispecific antibodies and immune-oncology program.
Ardena cements growth and expansion with new HQ cphi-online
November 14, 2018
Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.
ABL Awarded BARDA Contract contractpharma
April 14, 2017
ABL has been awarded a five-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSO100201600019I entitled...